Previous studies have shown that, among antihyperglycemic medication, insulin and sulfonylurea may increase the risk of cancer by interacting with insulin and insulin like growth factor 1 (IGF-1) receptor signalling, which enhances proliferation and carcinogenesis [13, 14]. The gene discussed is INS; the disease is cancer.